Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study

A multicenter retrospective study—presented during the 2023 ASCO Annual Meeting—found that treatment with tucatinib/trastuzumab/capecitabine post–trastuzumab deruxtecan exposure has significant efficacy for patients with metastatic HER2-positive breast cancer.